Sign In
Buy OKYO
$1.66
-0.0400 (-2.35%)
At Close: Jun 03, 2026
OpenAI back on top as GPT-5.2 calms competition concerns: Jefferies
07:56am, Friday, 12'th Dec 2025
OpenAI has quickly reasserted its lead in the AI race following concerns it was falling behind Google, analysts at Jefferies say, pointing to the release of...
Costco posts strong Q1 results as digital sales surge
03:54am, Friday, 12'th Dec 2025
Costco Wholesale Corporation (NASDAQ:COST, XETRA:CTO) reported an 8% rise in first-quarter revenue on Thursday aftermarket, lifted by robust digital...
Jiangxi Copper ups its approach for SolGold with 28p-a-share proposal
03:31am, Friday, 12'th Dec 2025
SolGold PLC (LSE:SOLG, TSX:SOLG, OTC:SLGGF) has confirmed it is warming to a sweetened takeover proposal from Jiangxi Copper, which has lifted its...
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study
09:44am, Thursday, 11'th Dec 2025
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP), said patients treated with its investigational therapy urcosimod in
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study
04:40am, Thursday, 11'th Dec 2025
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP), said patients treated...
OKYO Pharma Announces Chairman and Founder Acquires Shares
07:00am, Wednesday, 03'rd Dec 2025
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic cornea
OKYO Pharma Announces Chairman and Founder Acquires Shares
08:30am, Friday, 21'st Nov 2025
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
OKYO Pharma to Present at OIS XV in San Diego
08:30am, Tuesday, 18'th Nov 2025
LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
OKYO Pharma Announces Chairman and Founder Acquires Shares
08:30am, Thursday, 16'th Oct 2025
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
OKYO Pharma reports company stock purchase by executive chair
04:49am, Thursday, 16'th Oct 2025
OKYO Pharma Ltd (NASDAQ:OKYO) said it has been informed that Panetta Partners Limited, an entity in which the company’s executive chairman Gabriele Cerrone...
OKYO Pharma maps out registration path with 100-patient trial of Urcosimod for neuropathic corneal pain
08:47am, Monday, 22'nd Sep 2025
OKYO Pharma Ltd (NASDAQ:OKYO) plans to run a 100-patient, multi-centre study of its eye-drop candidate Urcosimod in neuropathic corneal pain, laying out a path it hopes can lead to US approval in a c
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
08:30am, Monday, 22'nd Sep 2025
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI
11:51am, Saturday, 19'th Jul 2025
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy
09:31am, Thursday, 17'th Jul 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its lead drug candidate for neuropathic corneal pain (NCP). NCP is
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain
09:42am, Wednesday, 16'th Jul 2025
OKYO Pharma Ltd (NASDAQ:OKYO) on Wednesday reported promising top-line results from a Phase 2 trial of its investigational drug urcosimod for neuropathic corneal pain (NCP), with 75% of patients showi
